Tectonic Therapeutic (TECX) CFO receives 7,500 performance stock options at $16.80

Rhea-AI Filing Summary

Tectonic Therapeutic, Inc. reported that Chief Financial Officer Daniel Lochner received a grant of performance stock options covering 7,500 shares of common stock. The options have an exercise price of $16.80 per share, expire on June 19, 2034, and are fully vested and immediately exercisable as of June 1, 2026. The 7,500 shares represent 50% of a larger performance-based award already earned after the board certified certain performance goals, while the remaining 50% will be earned only if additional performance criteria are met.

Insights

Equity compensation analyst

CFO received 7,500 fully vested performance stock options as routine pay.

Chief Financial Officer Daniel Lochner was granted performance stock options for 7,500 shares of Tectonic Therapeutic common stock at an exercise price of $16.80 per share. This award reflects performance already certified by the board on June 11, 2026.

The footnotes explain that these options are part of a larger performance-based package, with this portion representing 50% of the total award earned so far. The remaining 50% depends on additional performance criteria, underscoring an incentive structure tied directly to company results.

The options are fully vested and immediately exercisable as of June 1, 2026, meaning the CFO can convert them into shares at any time before the June 19, 2034 expiration. As a compensation-related, non-market transaction, this filing is generally neutral from a trading-sentiment standpoint.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lochner Daniel

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Performance Stock Option (Right to Buy)	7,500	$0.00	--

Holdings After Transaction: Performance Stock Option (Right to Buy) — 7,500 shares (Direct, null)

Footnotes (1)

1. Represents the number of shares earned under a performance-based stock option award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based conditions of the option award, the option was not reportable under Section 16 until the performance conditions were certified by the Issuer's Board of Directors, which occurred on June 11, 2026. The option reported on this form represents 50% of the total number of shares underlying the performance option subject to the option award. The remaining 50% of the shares will be earned upon the satisfaction of additional performance criteria. The shares underlying the option are fully vested and immediately exercisable as of June 1, 2026.

Key Figures

Options granted: 7,500 shares Exercise price: $16.80 per share Expiration date: June 19, 2034 +3 more

6 metrics

Options granted 7,500 shares Performance stock option award to CFO

Exercise price $16.80 per share Performance stock option exercise price

Expiration date June 19, 2034 Option term end date

Shares after transaction 7,500 derivative securities Total options held following grant

Earned portion of award 50% of total performance option Portion earned under certified performance criteria

Vesting status date June 1, 2026 Fully vested and immediately exercisable as of this date

Key Terms

Performance Stock Option, performance-based stock option award, Section 16, vested and immediately exercisable, +1 more

5 terms

Performance Stock Option financial

"Performance Stock Option (Right to Buy)"

performance-based stock option award financial

"Represents the number of shares earned under a performance-based stock option award"

Section 16 regulatory

"the option was not reportable under Section 16 until the performance conditions were certified"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

vested and immediately exercisable financial

"The shares underlying the option are fully vested and immediately exercisable as of June 1, 2026."

performance criteria financial

"will be earned upon the satisfaction of additional performance criteria."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lochner Daniel

(Last) (First) (Middle)

C/O TECTONIC THERAPEUTIC, INC.

490 ARSENAL WAY, SUITE 200

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tectonic Therapeutic, Inc. [ TECX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Stock Option (Right to Buy)	$16.8	06/11/2026		A		7,500(1)		(2)	06/19/2034	Common Stock	7,500	$0	7,500	D

Explanation of Responses:

1. Represents the number of shares earned under a performance-based stock option award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based conditions of the option award, the option was not reportable under Section 16 until the performance conditions were certified by the Issuer's Board of Directors, which occurred on June 11, 2026. The option reported on this form represents 50% of the total number of shares underlying the performance option subject to the option award. The remaining 50% of the shares will be earned upon the satisfaction of additional performance criteria.

2. The shares underlying the option are fully vested and immediately exercisable as of June 1, 2026.

	/s/ Daniel Lochner	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Tectonic Therapeutic (TECX) disclose about CFO Daniel Lochner in this Form 4?

Tectonic Therapeutic reported that CFO Daniel Lochner received a grant of performance stock options for 7,500 shares of common stock. These options are tied to performance goals already certified by the board and form part of his equity compensation package.

How many Tectonic Therapeutic (TECX) shares are covered by the new option grant?

The option award covers 7,500 shares of Tectonic Therapeutic common stock. According to the filing, this portion represents 50% of the total performance-based option award that has been earned so far under the specified performance criteria.

What is the exercise price and expiration date of the TECX CFO’s performance stock options?

The performance stock options have an exercise price of $16.80 per share and expire on June 19, 2034. This means the CFO can purchase shares at $16.80 up until that expiration date, provided the options remain outstanding.

When did Tectonic Therapeutic’s board certify the performance criteria for these options?

The board of Tectonic Therapeutic certified the relevant performance conditions on June 11, 2026. Only after this certification did the 7,500 performance-based options become reportable under Section 16, according to the detailed footnote in the filing.

Are the TECX CFO’s performance stock options already vested and exercisable?

Yes. The filing states that the shares underlying the option are fully vested and immediately exercisable as of June 1, 2026. This allows the CFO to exercise the options at any time before their June 19, 2034 expiration, subject to applicable rules.

What portion of the TECX performance option award remains subject to future performance?

The 7,500 options reported represent 50% of the total performance option award. The remaining 50% of shares will only be earned if additional performance criteria are satisfied, aligning a significant part of the award with future company results.